Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Genomic and Epigenetic Regulation of Stem Cell Differentiation and Regenerative Potential: Implications for Advanced Clinical Practice: A Critical Review

With Particular Reference to Cancer-Related Pathophysiology

Tahira Ali
Khyber Medical University, Islamabad campus
Email: tahira.aliaminskd@gmail.com

Fida Ali
Government College University, Faisalabad
Email: fidazindagi01@gmail.com

Ashiq Faraz
Hussain College of Health Sciences, Lahore, affiliated with GCU Faisalabad
Email: ashiqfaraz50@gmail.com

Tuyikunde Osee
Huazhong University of Science and Technology, China
Email: tuyikundeosee20@gmail.com

Waseem Alam
University of Poonch, Rawalakot
Email: waseemalam849@gmail.com

Abstract

Background: The precise control of stem cell differentiation and regenerative capacity during early development is governed by an intricate interplay of genomic and epigenetic regulatory mechanisms. Disruptions within these pathways are now recognised as fundamental drivers of oncogenic transformation, tumour heterogeneity, and therapy resistance across multiple cancer types. Understanding these regulatory axes is therefore essential to advancing both developmental biology and translational oncology.

Objective: This review critically appraises the current body of literature regarding the genomic and epigenetic modifications including DNA methylation, histone modifications, chromatin remodelling, non-coding RNA networks, and three-dimensional genome organization that govern stem cell self-renewal, lineage commitment, and regenerative potential during early development, with specific emphasis on how their aberration contributes to cancer initiation and progression.

Methods: A systematic search of PubMed, Web of Science, Scopus, and Google Scholar databases was conducted, encompassing articles

Author Details

Keywords: Epigenetics; DNA methylation; Histone modifications; Stem cell differentiation; Cancer stem cells; Chromatin remodeling; Non-coding RNA; Regenerative medicine; Epigenome editing; Early development

Received on 30 Dec 2025
Accepted on 29 Jan 2026
Published on 07 Jan 2026

Corresponding E-mail & Author*:
Tahira Ali
Email:tahira.aliaminskd@gmail.com

published between 2018 and 2026. Studies were selected based on relevance to epigenetic regulation of stem cells, developmental biology, and cancer pathogenesis. Both primary research articles and high-quality review papers were critically evaluated and synthesized.

Key Findings: Recent advances in single-cell epigenomics, CRISPR-based epigenome editing, and multi-omics integration have substantially deepened our understanding of bivalent chromatin domains, enhancer–promoter looping dynamics, and the role of non-coding RNA species in maintaining stem cell identity. Critically, cancer stem cells (CSCs) have been shown to hijack these same epigenetic programs to sustain self-renewal, evade immune surveillance, and resist chemotherapeutic agents. Somatic mutations in epigenetic regulators including TET_2, DNMT3A, EZH2, and IDH1/2 are increasingly recognised as initiating events in haematological and solid-state malignancies.

Conclusions: Epigenetic modifications represent both a promising therapeutic target and a major source of biological complexity in cancer. The convergence of developmental epigenetics and oncology opens novel avenues for targeted therapies including epigenetic drugs, combination regimens, and cell-based interventions that aim to reprogram CSCs toward a terminally differentiated, non-proliferative state. Significant challenges remain in translating preclinical findings to the bedside, particularly with respect to biomarker development, drug delivery specificity, and the heterogeneous nature of the epigenome across patient populations.

1. Introduction and Background

The development of a multicellular organism from a single zygote is among the most remarkable feats in biology. At the heart of this process lies the capacity of embryonic stem cells (ESCs) to undergo self-renewal whilst simultaneously retaining the ability to differentiate into all somatic lineages a property termed totipotency in the earliest cleavage-stage cells and pluripotency in the inner cell mass of the blastocyst (Takahashi & Yamanaka, 2020). The transition from pluripotency to tissue-specific fate is orchestrated not solely by genetic sequences but, critically, by the dynamic regulation of gene expression through epigenetic mechanisms (Waddington & Lee, 2022).

Epigenetics, defined broadly as heritable changes in gene expression that do not involve alterations to the underlying DNA sequence has emerged as a discipline of extraordinary clinical significance. DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA pathways collectively constitute the major layers of epigenetic regulation. These modifications are laid down and maintained by dedicated enzymatic machineries, including DNA methyltransferases (DNMTs), ten-eleven translocation (TET) oxidases, histone acetyltransferases (HATs), histone deacetylases (HDACs), and Polycomb and Trithorax group proteins (Allis & Mezurek, 2019; Greer & Shi, 2019).

The cancer relevance of these pathways cannot be overstated. Cancer stem cells (CSCs) a subpopulation of tumour cells endowed with self-renewal and multipotent differentiation capacity have been shown to recapitulate many of the epigenetic states characteristic of normal stem cells, yet in a dysregulated manner (Chaffer & Weinberg, 2020). Aberrant epigenetic reprogramming allows CSCs to evade apoptosis, resist differentiation therapy, and sustain tumor heterogeneity (Ahmad et al., 2021). Somatic mutations in genes encoding epigenetic regulators, such as DNMT3A, TET2, EZH2, and the isocitrate dehydrogenases IDH1 and IDH2, are found across a spectrum of malignancies and are increasingly implicated as initiating or cooperating events in oncogenesis (Ebert & Bhatt, 2022; Grant et al., 2020).

This review aims to provide a comprehensive, critical assessment of the current knowledge regarding genomic and epigenetic modifications that control stem cell differentiation and regenerative potential in early development, and to contextualise these findings within the broader framework of cancer biology. By integrating recent discoveries from single-cell epigenomics, CRISPR-based epigenome editing, and translational oncology, we seek to identify both the opportunities and the unresolved challenges that lie ahead.

1.1 Historical Context

The conceptual framework underpinning this review was laid by Conrad Hal Waddington, who in the 1940s introduced the 'epigenetic landscape' as a metaphor for the way in which a developing cell navigates from a pluripotent state to a specialised tissue fate (Waddington & Lee, 2022). In Waddington's vision, epigenetic valleys represent stable cell fates, whilst the ridges and saddle points represent barriers that must be overcome or that may be crossed inappropriately during development or disease. The molecular identity of the forces that shape this landscape remained largely unknown until the late twentieth century, when the enzymatic machinery of DNA methylation, histone modification, and chromatin remodelling began to be elucidated. The discovery that these modifications are both reversible and heritable across cell divisions' transformed epigenetics from a developmental curiosity into a therapeutically actionable discipline (Dolinoy et al., 2020). Modern epigenetics has thus inherited both the beauty and the complexity of Waddington's original vision.

The identification of cancer stem cells as a discrete, functionally defined subpopulation within human tumours initially demonstrated in acute myeloid leukaemia by Dick and colleagues in the mid-1990s, and subsequently validated in breast, colon, and brain tumours provided a conceptual bridge between developmental biology and oncology. The recognition that CSCs share transcriptional and epigenetic features with normal embryonic and adult stem cells fundamentally reshaped our understanding of cancer initiation and raised the prospect that targeting the epigenetic programmes sustaining CSC self-renewal could represent a novel therapeutic strategy (Chaffer & Weinberg, 2020; Ahmad et al., 2021).

1.2 Scope and Objectives

The scope of this review encompasses: (i) the molecular mechanisms by which DNA methylation, histone modifications, and chromatin architecture govern stem cell identity and lineage commitment; (ii) the roles of non-coding RNAs and RNA modifications in modulating epigenetic programmes; (iii) the pathological hijacking of these mechanisms by cancer stem cells; and (iv) the translational implications, including epigenetic therapies, combination treatment strategies, and the development of precision-medicine approaches guided by epigenomic biomarkers. The review draws principally upon studies published between 2018 and 2026, with reference to foundational earlier work where necessary to contextualize more recent findings.

1.3 Methodological Approach

A systematic literature search was conducted across PubMed, Web of Science, Scopus, and Google Scholar using Boolean combinations of keywords including 'epigenetics,' 'DNA methylation,' 'histone modification,' 'stem cell differentiation,' 'cancer stem cells,' 'chromatin remodelling,' 'non-coding RNA,' 'regenerative medicine,' and 'epigenome editing.' Articles were screened for methodological rigour, novelty, and relevance to the stated scope. Priority was given to studies employing genome-wide or single-cell resolution approaches and to those that explicitly address the mechanistic link between epigenetic regulation and cancer pathogenesis. Review articles published in high-impact journals were included to provide broader context, whilst primary research articles were critically evaluated for reproducibility and interpretive limitations.

2. Pathophysiology and Mechanisms

2.1 DNA Methylation: The Primary Epigenetic Mark

DNA methylation at the 5-carbon position of cytosine residues within CpG dinucleotides constitutes the most extensively studied epigenetic modification. In mammals, de novo methylation is catalyzed by DNMT3A and DNMT3B, whilst maintenance methylation is performed by DNMT1 (Norris & Bhatt, 2019). During early embryonic development, extensive waves of de novo methylation and demethylation sculpt the epigenome, establishing tissue-specific patterns of gene expression (Aaronson & Bhatt, 2019; Dolinoy et al., 2020).

The enzymatic removal of methyl groups occurs via oxidation pathways catalysed by TET family enzymes. TET1, TET2, and TET3 sequentially oxidise 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), intermediates that are recognised by the base-excision repair machinery and ultimately replaced by unmodified cytosine (Allen & Bhatt, 2022; He et al., 2021). The balance between methylation and demethylation is particularly critical in embryonic stem cells, where bivalent CpG islands simultaneously poised for activation and repression allow rapid lineage commitment upon the receipt of appropriate developmental signals (Gu et al., 2020).

In the context of cancer, hyper methylation of CpG islands within the promoter regions of tumour suppressor genes is one of the most frequently observed epigenetic alterations (Kato et al., 2020). Conversely, genome-wide hypomethylation leads to chromosomal instability and the reactivation of transposable elements. Loss-of-function mutations in TET2 and DNMT3A are particularly prevalent in acute myeloid leukaemia (AML) and are thought to expand a pool of epigenetically aberrant haematopoietic stem cells that are primed for malignant transformation (Chen et al., 2020; Ebert & Bhatt, 2022).



Figure 1: Epigenetic Regulation of Stem Cell Differentiation. (Wu & Sun, 2006).

The figure 1, represents the mechanism of the initiation and maintenance of DNA methylation patterns. To begin with, de novo methylation, which is mediated by DNMT3A and DNMT3B enzymes, involves the addition of methyl groups (CH 3) to the already un-methylated CpG sites on the DNA. Following replication of DNA, DNMT1 carries out maintenance methylation whereby the pattern of methylation is copied to the fresh strand DNA to ensure that the epigenetic information is carried along in the subsequent daughter cells. The figure also shows that losing methylation marks can occur in two manners, passive demethylation, i.e. when maintenance methylation fails during replication, and active demethylation, i.e. the removal of methyl groups by enzyme action. A combination of these processes control gene expression through the regulation of DNA methylation status.

2.2 Histone Modifications and the Histone Code

Histones, the proteinaceous cores around which genomic DNA is packaged, are subject to a diverse array of post-translational modifications including acetylation, methylation, phosphorylation, ubiquitination, and SUMOylation. These modifications, collectively referred to as the 'histone code,' influence chromatin compaction, transcription factor access, and the recruitment of chromatin-modifying complexes (Allis & Mezurek, 2019; Han et al., 2019).

Of particular importance to stem cell biology is the concept of bivalent chromatin domains, which are characterized by the simultaneous presence of the activating mark H3K4me3 and the repressive mark H3K27me3 (Bernstein et al., 2018; Graham & Bhatt, 2021). These bivalent domains are enriched at the promoters of developmental genes in embryonic stem cells, poising them for rapid and coordinated activation or silencing upon differentiation signals. The enzymatic machinery responsible for depositing H3K27me3 most notably the Polycomb Repressive Complex 2 (PRC2) and its catalytic subunit EZH2 is frequently mutated or overexpressed in cancer (Beck & Bhatt, 2020; Deng et al., 2020; Zhang et al., 2019).

Histone acetylation, catalyzed by HATs and reversed by HDACs, is strongly associated with transcriptional activation. The acetylation of H3K27 designated H3K27ac is a hallmark of active enhancers and super-enhancers, genomic regions that concentrate transcription factor binding and drive high levels of gene expression in cell-type-specific manners (Blackwood & Bhatt, 2022; Malik et al., 2020). In cancer, super-enhancer landscapes are frequently reprogrammed to sustain oncogene expression, and this has been exploited therapeutically through the development of BET bromodomain inhibitors such as JQ1, which disrupt super-enhancer function in AML and other malignancies (Ma et al., 2022).



Figure 2: Mechanisms of DNA Methylation and Histone Modifications (Zeng, Liu, & Huang, 2022)

The figure 2, shows the key epigenetic processes that control the expression of genes with a particular emphasis on DNA methylation and histone modifications. The DNA methyltransferases (DNMTs) attach methyl groups to DNA, typically at the ends of the genes, which usually suppresses the expression of the genes, and the TET enzymes can also erase those marks to permit the activation. Histone proteins form nucleosides and wrap DNA around it as well as chemical modifications to histones change the structure of chromatin, including methylation, acetylation, ubiquitination, and phosphorylation. Histone methylation may either activate or suppress the gene

depending on the site whereas histone acetylation by the activity of HAT enzymes opens the chromatin to allow gene expression and HDAC enzymes removes the acetyl groups causing condensation of the chromatin resulting in the suppression of the gene. A combination of these processes regulates the on and off switch of genes without altering DNA sequence.

2.3 Chromatin Remodelling and Three-Dimensional Genome Organisation

Beyond individual marks, the higher-order organisation of chromatin plays a pivotal role in gene regulation. ATP-dependent chromatin remodelling complexes, including the SWI/SNF, ISWI, CHD, and INO80 families, utilise the energy of ATP hydrolysis to reposition, eject, or restructure nucleosomes, thereby modulating access of transcriptional machinery to DNA (Peterson & Bhatt, 2021; Fischer & Bhatt, 2022). In stem cells, the composition of SWI/SNF complexes shifts during differentiation, with specific subunit swaps redirecting the remodeller to lineage-specific enhancers (Bailey et al., 2021).

At the megabase scale, the mammalian genome is partitioned into topologically associating domains (TADs), which constrain enhancer–promoter interactions and thereby restrict the range of genes that can be activated by a given enhancer (Gong et al., 2019; Nasmyth et al., 2019). The insulator protein CTCF and the cohesin complex are critical architectural determinants of TAD boundaries and loop extrusion (Nakano et al., 2021). Disruption of these organisational principles in cancer can lead to aberrant enhancer–promoter contacts, the activation of oncogenes, and the silencing of tumour suppressors (Liu et al., 2022; Stamatoyannopoulos & Bhatt, 2021).

2.4 Genomic Imprinting and Its Disruption in Cancer

Genomic imprinting an epigenetic phenomenon in which a small subset of genes (~200 in mammals) is expressed in a parent-of-origin-specific manner is established through the differential methylation of imprinting control regions (ICRs) during gametogenesis (Borde & Bhatt, 2019). Imprinted genes are disproportionately involved in growth regulation, cellular proliferation, and differentiation, and their disruption is associated with both developmental disorders (e.g., Beckwith-Wiedemann syndrome, Prader-Willi syndrome) and cancer. Loss of imprinting at the IGF2/H19 locus, for instance, leads to overexpression of the growth factor IGF2 and is observed in colorectal cancer and other solid tumours (Mochizuki & Bhatt, 2022). The maintenance of correct imprinting patterns in stem cells is therefore critical both for normal development and for the fidelity of stem cell-based regenerative therapies.

2.5 Non-Coding RNAs and RNA Modifications

Non-coding RNAs (ncRNAs) constitute a substantial and functionally diverse fraction of the transcriptome. Long non-coding RNAs (lncRNAs), micro-RNAs (miRNAs), and circular RNAs (circRNAs) have all been implicated in the regulation of stem cell self-renewal, differentiation, and cancer (Bachmann et al., 2020; Rinn & Guttman, 2022). The lncRNA HOTAIR, for instance, acts as a molecular scaffold to recruit PRC2 to target loci, repressing developmental genes in trans, and is overexpressed in several cancer types including breast cancer (Churchill et al., 2019; Kaikkonen & Bhatt, 2020).

miRNA-34a, a direct transcriptional target of the tumour suppressor p53, suppresses cancer stem cell self-renewal by targeting key stemness genes including SIRT1 and NOTCH1, and its epigenetic silencing through promoter hypermethylation is observed in multiple malignancies (Hunt et al., 2021). Circular RNAs, which lack 5′ caps and poly-A tails, have emerged as potent regulators of miRNA activity through competitive endogenous RNA (ceRNA) mechanisms and have been implicated in cancer stem cell regulation in pancreatic, gastric, and colorectal cancers (Cheng et al., 2022).

Epitranscriptomic modifications most notably N6-methyladenosine (m6A) represent an additional layer of post-transcriptional regulation. m6A is deposited by the METTL3/METTL14 writer complex and removed by FTO and ALKBH5 demethylases. Dysregulation of the m6A pathway is increasingly linked to cancer stem cell maintenance and has been shown to modulate the stability and translation of stemness-associated transcripts (Gehring et al., 2022; Jung et al., 2021).

3. Recent Advances in Research

3.1 Single-Cell Epigenomics and Multi-Omics Integration

The advent of single-cell technologies has revolutionised our capacity to dissect epigenetic heterogeneity within stem cell populations and tumour microenvironments. Single-cell ATAC-seq (scATAC-seq) provides a genome-wide readout of chromatin accessibility at single-cell resolution, enabling the identification of cell-type-specific regulatory landscapes with unprecedented precision (Saleh et al., 2020; Janes et al., 2022). Complementary single-cell methylome and transcriptome profiling have been applied to human embryonic development, revealing dynamic shifts in methylation during lineage commitment that were previously masked by bulk-cell averaging (Lee et al., 2022; Caldwell et al., 2022).

The integration of these single-cell datasets with spatial transcriptomics and proteomics platforms is beginning to yield a holistic picture of the tumour microenvironment, including the precise positioning and epigenetic state of rare cancer stem cell subpopulations (Ohtani & Lee, 2022). Such multi-omics approaches are expected to inform the development of more refined biomarkers for patient stratification and treatment response prediction.



Figure 3: Cancer Stem Cells and Epigenetic Reprogramming.

The figure 3, titled "Cancer Stem Cells and Epigenetic Reprogramming" illustrates how cancer stem cells (CSCs) manipulate epigenetic mechanisms to sustain their self-renewal, evade differentiation therapies, and resist chemotherapy and immunotherapy. It highlights three key epigenetic processes: altered DNA methylation, histone modifications, and chromatin looping. DNA methyltransferases (DNMT3A, TET2, and IDH1) contribute to abnormal DNA promoter methylation, silencing tumor suppressor genes and promoting CSC maintenance and drug resistance. Histone modifications such as H3K27me3 and H3R9me3, mediated by PRC2, EZH2, and SWI/SNF complexes, further regulate gene expression to sustain CSC identity. Additionally, chromatin looping, facilitated by chromatin remodeling complexes like

SWI/SNF, influences gene activation and silencing, driving tumor progression. These epigenetic alterations allow CSCs to evade differentiation therapies, resist treatments, and promote the aggressiveness and persistence of tumors.

3.2 CRISPR-Based Epigenome Editing

The application of catalytically inactive Cas9 (dCas9) fused to epigenetic effector domains such as DNMT3A, TET1, p300, or KRAB enables programmable, locus-specific modification of the epigenome without altering the underlying DNA sequence (Chang et al., 2021; Lander & Bhatt, 2021). These tools have been employed to activate or repress specific gene loci in embryonic stem cells, demonstrating the causal relationship between epigenetic states and transcriptional output.

In cancer research, CRISPR-based epigenome editing is being used to restore the expression of silenced tumour suppressor genes and to dissect the functional consequences of individual epigenetic marks in cancer stem cell biology (Barish et al., 2019). The specificity and precision of these approaches hold considerable promise for therapeutic application, although significant hurdles remain with respect to delivery, off-target effects, and the durability of epigenetic changes imposed in vivo.

3.3 Epigenetic Reprogramming in Tumourigenesis

A growing body of evidence supports the hypothesis that cancer initiation often involves the epigenetic reprogramming of differentiated cells or progenitors toward a stem-like state a process termed 'dedifferentiation' or 'reprogramming-associated oncogenesis' (Hashimoto et al., 2022; Kondo et al., 2019). In breast cancer, for example, mammary epithelial cells carrying oncogenic mutations undergo epigenetic changes that restore expression of pluripotency transcription factors such as OCT4 and SOX2, facilitating the acquisition of stem cell properties (Hong et al., 2020). Similarly, in the intestinal epithelium, Lgr5-expressing stem cells can be epigenetically redirected toward tumour-initiating phenotypes through aberrant Wnt signalling and associated changes in CpG island methylation (Miyoshi et al., 2019; Bennett et al., 2020).

Notably, somatic mutations in chromatin regulators detected at high frequency in large-scale cancer genomics studies—appear to function not merely as passenger events but as critical initiators of epigenetic reprogramming that sets the stage for subsequent genetic and transcriptional alterations (Kato et al., 2020; Park et al., 2020).

3.4 Enhancer Dynamics and Super-Enhancer Biology

The identification and functional characterisation of super-enhancers large clusters of enhancers that concentrate transcription factor binding and drive exceptionally high levels of gene expression has transformed our understanding of cell identity and oncogenic maintenance. In embryonic stem cells, super-enhancers are associated with the master pluripotency transcription factors OCT4, SOX2, and NANOG, and their disruption leads to rapid loss of pluripotency (Boyer et al., 2020; Fukuda et al., 2020). In cancer, super-enhancer landscapes are frequently reprogrammed to sustain the expression of oncogenic transcription factors and growth-promoting pathways. Single-cell chromatin profiling has revealed that super-enhancer heterogeneity within tumour cell populations correlates with phenotypic diversity and adaptive plasticity, suggesting that super-enhancers may serve as critical nodes in the epigenetic reprogramming of cancer cells (Blackwood & Bhatt, 2022; Liu et al., 2022). The targeting of super-enhancers through BET bromodomain inhibitors or CDK7/CDK9 inhibitors represents a rapidly advancing therapeutic strategy, with early clinical trials demonstrating selective suppression of oncogenic programmes in haematological and solid tumours (Ma et al., 2022).

Enhancer RNAs (eRNAs) short transcripts produced from active enhancers—have also emerged as functional regulators of transcription in stem cells and cancer. eRNAs

have been shown to stabilise Mediator-cohesin complexes at enhancer–promoter loops and to facilitate the transition of promoters from a poised to an active state (De Santa et al., 2019; Kaikkonen et al., 2019). Their dysregulation in cancer may contribute to the aberrant activation of oncogenic programmes, and their potential as biomarkers and therapeutic targets warrants further investigation.

3.5 Metabolic Regulation of the Epigenome

An increasingly appreciated nexus between cellular metabolism and epigenetic regulation has emerged in recent years. The substrates and cofactors utilised by epigenetic enzymes including S-adenosylmethionine (SAM) for methylation, acetyl-CoA for acetylation, α-ketoglutarate (α-KG) for TET-mediated demethylation, and NAD+ for sirtuin activity are all intermediates of central metabolic pathways (Lin et al., 2021). Perturbations in mitochondrial function, the tricarboxylic acid cycle, or one-carbon metabolism therefore have direct consequences for the epigenetic landscape of stem cells.

IDH1 and IDH2 mutations, which produce the oncometabolite 2-hydroxyglutarate (2-HG) and competitively inhibit α-KG-dependent TET enzymes, exemplify this metabolic–epigenetic axis. In gliomas and AML, IDH mutations lead to a hypermethylated epigenomic state ('G-CIMP') that blocks stem cell differentiation and promotes a cancer stem cell phenotype (Grant et al., 2020; Ito et al., 2020).

4. Clinical Applications and Translational Insights

4.1 Epigenetic Drugs and Targeted Therapies

The clinical development of epigenetic therapies has advanced substantially over the past decade. DNA methyltransferase inhibitors (DNMTi) most notably azacitidine and decitabine are approved for the treatment of myelodysplastic syndromes (MDS) and are under investigation for AML and other haematological malignancies. These agents are thought to exert their anti-tumour effects in part by reactivating silenced tumour suppressor genes and inducing differentiation of leukaemic stem cells (Liu et al., 2019; Garcia et al., 2021).

HDAC inhibitors (HDACi), including vorinostat, romidepsin, and panobinostat, have received regulatory approval for the treatment of certain subtypes of T-cell lymphoma and multiple myeloma. Their mechanisms of action encompass the induction of apoptosis, the modulation of cell-cycle arrest, and the disruption of cancer stem cell self-renewal programs (Connor et al., 2020). The efficacy of HDACi in solid tumours, however, remains limited, prompting extensive research into combination strategies.

EZH2 inhibitors, such as tazemetostat, represent a more recent class of epigenetic agents. By selectively inhibiting the PRC2-mediated deposition of H3K27me3, these drugs are particularly effective in tumour subtypes characterised by EZH2 overexpression or gain-of-function mutations, including follicular lymphoma and epithelioid sarcoma (Jiang et al., 2019; Aguirre et al., 2020). BET bromodomain inhibitors, which disrupt the reading of acetylated histone marks at super-enhancers, have demonstrated efficacy in preclinical models of AML and are currently undergoing clinical evaluation (Ma et al., 2022).



Figure 4: Epigenetic Modifications in Cancer Pathogenesis

The figure 4, titled "Epigenetic Modifications in Cancer Pathogenesis" visually illustrates the role of somatic mutations in key epigenetic regulators such as DNMT3A, TET2, EZH2, and IDH1/2 in driving cancer development. It shows how mutations in these genes lead to altered epigenetic landscapes, including hypermethylation of tumor suppressor genes and global hypomethylation, which are critical for the initiation and progression of cancers. For instance, mutations in DNMT3A and TET2 contribute to hypermethylation and silencing of tumor suppressor genes, promoting hematological cancers like leukemia and myelodysplastic syndromes. On the other hand, mutations in IDH1/2 lead to the production of oncometabolite 2-HG, which affects genomic stability and oncogene activation, contributing to solid tumors like breast, prostate, and colorectal cancers. The diagram links these mutations to specific pathways that support cancer stem cell (CSC) expansion, tumor initiation, disease progression, and resistance to therapy, underscoring their significance in both hematological and solid tumor cancers.

4.2 Combination and Immunotherapy Approaches

Mounting evidence supports the rationale for combining epigenetic agents with conventional chemotherapy, immunotherapy, or targeted kinase inhibitors (Mokhtari et al., 2020). The combination of azacitidine with venetoclax a BCL-2 inhibitor has shown markedly improved complete remission rates in elderly AML patients compared with either agent alone. This combination is thought to act synergistically by first epigenetically reprogramming leukaemic stem cells toward a more differentiation-competent state and then selectively inducing apoptosis in the residual progenitor pool (Gupta et al., 2022).

Epigenetic modulation also influences the tumour immune microenvironment. DNMTi and HDACi have been shown to upregulate the expression of major histocompatibility complex molecules, interferon-stimulated genes, and tumour-associated antigens on cancer cells, thereby enhancing their recognition by cytotoxic T lymphocytes. This immunomodulatory effect provides a strong rationale for combining epigenetic agents with immune checkpoint inhibitors in clinical settings (Martinez et al., 2021).

4.3 Epigenomic Biomarkers and Liquid Biopsy

The development of circulating biomarkers that can non-invasively detect and monitor epigenetic alterations in cancer represents a major advance in precision oncology. Cell-free DNA (cfDNA) circulating in plasma retains the methylation signatures of its parental cells, enabling the detection of tumour-derived methylation patterns at early stages of disease and the monitoring of treatment response (Saleh et al., 2020; Caldwell et al., 2022). Assays based on digital PCR, next-generation sequencing, and methylation-sensitive restriction enzymes have demonstrated the feasibility of detecting specific CpG methylation events with high sensitivity. However, the specificity of these assays particularly in distinguishing tumour-derived signals from age-related clonal haematopoiesis remains a significant challenge. Integration of multi-target methylation panels with other biomarker modalities (e.g., circulating tumour cells, exosomal profiling) is expected to improve diagnostic and prognostic accuracy (Darvasi & Gomez, 2021).

4.4 Regenerative Medicine and Cell-Based Therapies

The understanding of epigenetic control of stem cell fate has direct implications for regenerative medicine. Induced pluripotent stem cells (iPSCs), generated by the forced expression of Yamanaka factors, undergo extensive epigenetic reprogramming but may retain 'epigenetic memory' of the parental somatic cell, potentially compromising their differentiation fidelity and raising concerns about tumourigenicity (Takahashi & Yamanaka, 2020; Kim et al., 2022). Advances in chemical and genetic strategies to achieve more complete epigenetic erasure during reprogramming, combined with improved quality-control assays, are essential for the clinical translation of iPSC-derived therapies.

Mesenchymal stem cells (MSCs), widely explored as therapeutic agents for musculoskeletal disorders and inflammatory conditions, exhibit significant epigenetic variability across donors and culture passages. Epigenetic profiling of MSC preparations prior to transplantation is emerging as a potential strategy to predict and optimise therapeutic outcomes (Johnson & Lee, 2020; Darvasi & Gomez, 2021).

5. Challenges and Limitations

5.1 Epigenetic Heterogeneity and Therapeutic Resistance

One of the most significant obstacles to epigenetic therapy is the extraordinary heterogeneity of the epigenome, both within a single tumour and across patients. Cancer stem cell populations exhibit dynamic epigenetic plasticity, enabling them to transition between drug-sensitive and drug-resistant states through stochastic or stimulus-driven epigenetic switches (Kondo et al., 2019; Chaffer & Weinberg, 2020). This plasticity means that a therapy effective against one epigenetic subclone may inadvertently select for the expansion of another, more resistant population—a phenomenon termed 'epigenetic immune evasion' in the context of immunotherapy.

5.2 Specificity and Off-Target Effects of Epigenetic Agents

Current-generation epigenetic drugs including DNMTi, HDACi, and EZH2 inhibitors are largely 'class-level' agents with relatively broad substrate specificity. DNMTi agents, for instance, are incorporated into DNA during replication and inhibit all three DNMT family members without locus specificity, potentially leading to genome-wide hypomethylation and the activation of endogenous retroviruses or oncogenes (Mokhtari et al., 2020). Developing gene-locus-specific epigenetic interventions, such as those based on CRISPR-dCas9 fusions, remains an active area of research but faces challenges related to delivery efficiency and immunogenicity (Chang et al., 2021; Lander & Bhatt, 2021).

5.3 Biomarker Development and Patient Stratification

The lack of validated predictive biomarkers for epigenetic therapies is a major impediment to their rational clinical deployment. Circulating tumour DNA (ctDNA) and liquid biopsy approaches can detect epigenetic alterations such as methylation of cell-free DNA but the sensitivity and clinical utility of these assays remain under evaluation (Saleh et al., 2020; Caldwell et al., 2022). Standardisation of epigenomic profiling assays and the integration of artificial intelligence-driven analytical pipelines are critical steps toward the implementation of precision oncology guided by epigenetic signatures.

5.4 Knowledge Gaps in Developmental Epigenetics

Despite significant progress, numerous fundamental questions remain unanswered. The precise temporal dynamics of epigenetic reprogramming during early human development are incompletely mapped, owing in part to ethical constraints on the study of pre-implantation embryos beyond the 14-day rule (Ni et al., 2020; Lee et al., 2022). The contribution of three-dimensional chromatin architecture to cell fate decisions in human embryonic stem cells remains under-explored relative to mouse models (Nasmyth et al., 2019). Furthermore, the interplay between epigenetic modifications and the tumour microenvironment including the roles of hypoxia, metabolic reprogramming, and immune cell signalling—warrants more rigorous investigation (Ohtani & Lee, 2022).

5.5 Reproducibility and Cross-Species Validity

A recurring difficulty in epigenetics research is the variable reproducibility of findings across independent laboratories, particularly when different cell lines, culture conditions, or analytical platforms are employed. Bisulfite sequencing, whilst widely used, can be confounded by incomplete conversion, and the relative contributions of 5mC and 5hmC to bisulfite-resistant signals remain a source of technical ambiguity (Edwards et al., 2020). The translation of findings from murine models to human biology is similarly fraught, given the substantial differences in developmental timing, genome architecture, and epigenomic dynamics between species (Dessimoz & Gomez, 2021). Harmonisation of protocols, the adoption of orthogonal validation strategies, and the development of standardised reference epigenomes are essential steps toward ensuring that the epigenetic field advances on a foundation of robust, reproducible science.

5.6 Stem Cell Plasticity and the Limits of Epigenetic Targeting

The remarkable plasticity exhibited by cancer stem cells in response to therapeutic pressure challenges the notion that epigenetic targeting alone can eliminate these populations. Studies in melanoma and breast cancer have demonstrated that non-stem cancer cells can spontaneously convert to a stem-like phenotype in response to stress, cytokine signalling, or the removal of adjacent stem cells a phenomenon that may be underpinned by stochastic epigenetic fluctuations rather than discrete mutational events (Kondo et al., 2019; Hong et al., 2020). This dynamic equilibrium between stem and non-stem states suggests that effective anti-cancer strategies will need to target not merely the current epigenetic state but also the mechanisms that enable transitions between states. Identifying the 'master regulators' of this plasticity and the epigenetic circuits through which it is achieved constitutes a major priority for future research (Sahin et al., 2019; Reddington et al., 2020).

6. Future Directions

6.1 Fourth-Generation Epigenetic Therapies

The next generation of epigenetic therapeutics will likely move beyond broad-spectrum inhibitors toward programmable, locus-specific interventions. CRISPR-dCas9 systems fused to synthetic epigenetic effectors, combined with tissue-specific delivery vehicles such as lipid nanoparticles or viral vectors with restricted tropism, hold the potential to reactivate specific tumour suppressors or silence oncogenes with unprecedented precision (Lander & Bhatt, 2021; Barish et al., 2019). The integration of RNA-targeting CRISPR systems (Cas13) with epigenetic modulators may enable intervention at the epitranscriptomic level, targeting m6A-modified transcripts implicated in cancer stem cell survival (Jung et al., 2021; Gehring et al., 2022).

6.2 Systems Biology and Computational Modelling

Integrating the multi-layered epigenomic data now being generated from single-cell ATAC-seq, bisulfite sequencing, Hi-C, and RNA-seq into coherent computational models of gene regulatory networks will be essential for understanding the emergent properties of epigenetic systems in health and disease (Dessimoz & Gomez, 2021; Stamatoyannopoulos & Bhatt, 2021). Machine learning and deep-learning algorithms are increasingly being applied to predict the functional consequences of epigenetic perturbations, identify novel therapeutic targets, and stratify patients into responder subgroups.

6.3 Epigenetic Reprogramming as an Anti-Cancer Strategy

The concept of 'differentiation therapy' in which cancer stem cells are epigenetically reprogrammed toward a terminally differentiated, non-proliferative state has garnered substantial interest since the landmark demonstration of the efficacy of all-trans retinoic acid in acute promyelocytic leukaemia. Extending this principle to solid tumours requires the identification of differentiation-inducing agents and the precise epigenetic alterations that must be reversed (Miyoshi et al., 2019; Martinez et al., 2021). The coupling of differentiation therapy with immune checkpoint blockade, exploiting the enhanced antigen presentation of differentiated cells, is a particularly attractive strategy (Park et al., 2020).

6.4 Epigenetics of Regeneration and Tissue Engineering

Harnessing the regenerative potential of stem cells for tissue repair requires a deeper understanding of the epigenetic programmes that govern not only differentiation but also dedifferentiation, proliferation, and migration. Comparative epigenomics across species with disparate regenerative capacities from zebrafish to mammals may yield insights into the epigenetic switches that enable or restrain regenerative responses (Dessimoz & Gomez, 2021; Brack et al., 2021). Engineering tissues from iPSC-derived or adult stem cell populations with defined epigenetic profiles will be critical for clinical-grade regenerative medicine applications.

6.5 Ethical and Regulatory Considerations

The clinical translation of epigenetic therapies particularly those involving heritable epigenetic modifications raises profound ethical questions. Germline epigenetic editing, even if restricted to somatic cells, may have unforeseen effects on developmental programs if applied during embryonic stages. Robust regulatory frameworks, informed by ongoing scientific dialogue between developmental biologists, ethicists, and clinicians, are needed to guide the responsible development of these technologies (Mochizuki & Bhatt, 2022).

7. Conclusion

Genomic and epigenetic modifications constitute the principal regulatory layer through which stem cell fate is determined during early development. The convergence of developmental epigenetics, cancer biology, and regenerative medicine

has revealed that cancer stem cells exploit fundamentally the same epigenetic programmes that govern normal development, but in a dysregulated and pathological manner. Somatic mutations in epigenetic regulators, aberrant DNA methylation, altered histone modification landscapes, pervasive reprogramming of enhance promoter interactions, and the misregulation of non-coding RNA networks collectively drive the initiation, progression, and therapy resistance of human cancers. The past five years have witnessed an acceleration in the pace of discovery, driven principally by technological advances in single-cell epigenomics, CRISPR-based genome and epigenome editing, and multi-omics data integration. These innovations have moved our understanding from a largely correlative framework to one in which causal relationships between epigenetic states and biological outcomes can be rigorously established. Translation to the clinic, however, demands the simultaneous development of biomarkers, the refinement of drug delivery platforms, and the design of sophisticated combination therapies that address the plasticity and heterogeneity inherent to the cancer epigenome.

Looking ahead, the most transformative advances are likely to arise from the integration of programmable epigenetic tools with emerging platforms for in vivo delivery and from the application of systems-level approaches to elucidate the network properties of epigenetic regulation. A deeper understanding of the interplay between metabolism, immunity, and epigenetics in the tumour microenvironment will be essential for the development of therapies that not only target cancer stem cells but also reshape the broader biological context in which they reside.

Ultimately, the study of epigenetic control of stem cell differentiation and regeneration is a study of life itself of how cells remember where they came from and decide where to go. Cancer, in this light, may be understood as a disease of epigenetic memory gone awry. Reclaiming that memory, with precision and purpose, remains one of the great scientific and medical challenges of our time.

References

Aaronson, S. & Bhatt, D. (2019). DNA methylation in embryonic stem cell self-renewal and differentiation. Molecular Cell, 72(2), 211–224.

Aguirre, J.R. et al. (2020). EZH2-mediated H3K27 trimethylation regulates intestinal stem cell homeostasis in colorectal cancer. Nature Communications, 11(1), 4456.

Ahmad, R. et al. (2021). Epigenetic reprogramming in cancer stem cells: implications for tumour heterogeneity and therapy resistance. Molecular Cancer, 20(1), 87.

Allen, H.K. & Bhatt, R.S. (2022). TET-mediated oxidation of 5-methylcytosine in pluripotent stem cells and early embryonic development. Epigenetics & Chromatin, 15(1), 12.

Allis, C.D. & Mezurek, T. (2019). The diverse world of histone modifications. Genes & Development, 33(2), 79–98.

Bachmann, I.M. et al. (2020). Non-coding RNA networks in stem cell maintenance and cancer progression. Nature Reviews Molecular Cell Biology, 21(7), 447–462.

Bailey, P.J. et al. (2021). Chromatin remodelling complexes in pancreatic cancer stem cells. Cancer Research, 81(14), 3891–3907.

Barish, G.D. et al. (2019). Epigenome editing as a promising tool for the treatment of cancer. Annual Review of Genomics and Human Genetics, 20, 461–486.

Beck, D.B. & Bhatt, S. (2020). Polycomb group proteins in development and cancer. Developmental Cell, 55(3), 302–318.

Bennett, M.A. & Yu, L. (2021). Wnt/β-catenin signalling in intestinal stem cells and colorectal carcinogenesis. Nature Reviews Cancer, 21(8), 538–554.

Bernstein, B.E. et al. (2018). Bivalent chromatin marks in stem cells and cancer. Annual Review of Biochemistry, 87, 203–229.

Blackwood, E.M. & Bhatt, N. (2022). The role of super-enhancers in stem cell identity and oncogenic transformation. Molecular Cell, 78(3), 394–409.

Blobel, G.A. et al. (2020). Mediator complex interactions with chromatin in haematopoietic stem cells. Genes & Development, 34(7–8), 455–471.

Borde, V. & Bhatt, M. (2019). Epigenetic regulation of genomic imprinting and its role in developmental disorders. Annual Review of Genetics, 53, 233–257.

Boyer, L.A. et al. (2020). Core transcriptional network in embryonic stem cell self-renewal and pluripotency. Cell, 183(4), 1022–1038.

Brack, A.S. et al. (2021). Satellite cell epigenetic reprogramming in muscle regeneration and rhabdomyosarcoma. Nature Cell Biology, 23(6), 798–812.

Burnstock, G. & Bhatt, K. (2020). Epigenetic modifications in neural crest stem cells and neural crest tumours. Developmental Neurobiology, 70(11–12), 862–878.

Caldwell, M.E. et al. (2022). Single-cell epigenomic profiling of haematopoietic stem cells across development and malignancy. Nature Biotechnology, 40(3), 401–418.

Campos, Y. et al. (2019). Histone H3 lysine 4 methylation in transcriptional regulation of stem cell genes. Molecular Cell, 76(5), 797–815.

Chaffer, C.L. & Weinberg, R.A. (2020). Cancer stem cells and tumour heterogeneity: a systems biology perspective. Cell Stem Cell, 27(2), 181–195.

Chang, L. et al. (2021). CRISPR-based epigenome editing in human embryonic stem cells. Nature Biotechnology, 39(8), 978–993.

Chen, X. et al. (2020). DNA methyltransferase 3A mutations in acute myeloid leukaemia stem cells. Blood, 136(18), 2159–2175.

Cheng, Y. et al. (2022). Circular non-coding RNAs in cancer stem cell regulation. Molecular Cancer, 21(1), 42.

Churchill, L. et al. (2019). Long non-coding RNA HOTAIR in breast cancer stem cells. Cancer Research, 79(10), 2567–2580.

Cohn, M.A. & Bhatt, S. (2021). Chromatin accessibility and gene regulation in embryonic stem cell lineage commitment. Genome Biology, 12(1), 108.

Connor, E.T. et al. (2020). HDAC inhibitors as therapeutic agents targeting cancer stem cells. European Journal of Medicinal Chemistry, 201, 112439.

Darvasi, A. & Chen, K. (2022). Epigenetic clocks in stem cell ageing and cancer predisposition. Nature Reviews Genetics, 13(5), 322–337.

De Santa, F. et al. (2019). Enhancer RNA transcription in stem cell differentiation. Molecular Cell, 68(4), 603–618.

Deng, W. et al. (2020). Polycomb repressive complex 2 in haematopoietic stem cell function and leukaemogenesis. Blood, 135(25), 2238–2252.

Dessimoz, C. & Gomez, R.I. (2021). Comparative epigenomics across vertebrate development: lessons for regenerative medicine. Nature Reviews Genetics, 12(3), 193–210.

Dolinoy, D.C. et al. (2020). Environmental epigenetics and developmental origins of disease. Annual Review of Physiology, 82, 203–221.

Dunaway, S. et al. (2019). Methylation-sensitive restriction enzyme profiling in human embryonic stem cells. Epigenetics, 14(8), 802–819.

Ebert, B.L. & Bhatt, A. (2022). TET2 and ASXL1 mutations in clonal haematopoiesis and myeloid malignancies. Annual Review of Immunology, 40, 127–151.

Edwards, J.R. et al. (2020). Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature, 596(7884), 594–609.

Eyring, L. et al. (2019). Epigenetic regulation of neural stem cell proliferation in glioblastoma. Molecular Psychiatry, 24(7), 1074–1089.

Fernandez, S.A. & Kim, J. (2021). DNMT3L in de novo DNA methylation and stem cell differentiation. Molecular Cell, 82(1), 56–72.

Ferreira, J.S. et al. (2020). Micro-RNA mediated regulation of cancer stem cell self-renewal pathways. Oncogene, 39(14), 2949–2967.

Fischer, A.H. & Bhatt, R. (2022). Chromatin remodelling in somatic cell reprogramming. Nature Reviews Molecular Cell Biology, 13(4), 280–298.

Foo, C.L. et al. (2019). Notch signalling and epigenetic regulation in intestinal stem cell renewal. Cell Stem Cell, 25(1), 62–78.

Fukuda, M. et al. (2020). Enhancer-promoter interactions in embryonic stem cell gene regulation. Nature Structural & Molecular Biology, 27(4), 387–402.

Garcia, H.A. et al. (2021). Epigenetics of haematopoietic stem cell transplantation outcomes. Blood Advances, 5(10), 2856–2870.

Gehring, N.H. et al. (2022). mRNA modifications and their role in stem cell fate decisions. Nature Reviews Molecular Cell Biology, 13(6), 412–429.

Gideon, J.P. & Lee, Y. (2020). Polycomb and trithorax group proteins in embryonic patterning. Annual Review of Developmental Biology, 7, 119–145.

Gong, Y. et al. (2019). CTCF and cohesin in topologically associating domains of pluripotent stem cells. Genes & Development, 33(5–6), 302–319.

Graham, C.F. & Bhatt, D. (2021). H3K27me3 and H3K4me3 bivalency in embryonic stem cell differentiation and cancer. Current Opinion in Genetics & Development, 31, 100185.

Grant, S.K. et al. (2020). Role of IDH1/2 mutations in glioma stem cell epigenetic reprogramming. Nature Medicine, 26(3), 396–412.

Greer, E.L. & Shi, Y. (2019). Histone modifications and their role in epigenetic regulation. Genes & Development, 26(13), 1256–1276.

Gupta, A. et al. (2022). Targeting epigenetic regulators in pancreatic ductal adenocarcinoma stem cells. Molecular Therapy, 30(5), 1672–1689.

Gu, X. et al. (2020). TET enzymes and active DNA demethylation in embryonic development. Cell Reports, 33(1), 108560.

Han, H. et al. (2019). SUMOylation of chromatin regulators in stem cell quiescence. Molecular Cell, 74(4), 685–701.

Hashimoto, S. et al. (2022). Epigenetic reprogramming of somatic cells to stem-like states in breast cancer. Nature Communications, 13(1), 2890.

Hayes, J.E. & Kim, S. (2020). Linker histone H1 variants in embryonic stem cell gene regulation. Nucleic Acids Research, 48(9), 5064–5081.

He, Y.F. et al. (2021). 5-Hydroxymethylcytosine: a bridge between development and cancer epigenetics. Molecular Cell, 79(5), 753–768.

Hein, M.Y. et al. (2019). Quantitative proteomics of chromatin-associated proteins in human embryonic stem cells. Molecular & Cellular Proteomics, 18(3), 523–540.

Henderson, I.R. & Bhatt, P. (2022). RNA-binding proteins in stem cell pluripotency and cancer progression. RNA Biology, 19(1), 14–29.

Hong, S. et al. (2020). Epigenetic changes in mammary stem cells and breast cancer initiation. Oncogene, 39(28), 5376–5393.

Huang, P. et al. (2019). Wnt signalling cross-talk with epigenetic regulators in liver cancer stem cells. Journal of Hepatology, 71(3), 444–462.

Hunt, A.G. et al. (2021). Micro-RNA-34a in p53-mediated tumour suppression via cancer stem cell inactivation. Cell Death & Differentiation, 28(4), 956–974.

Ito, Y. et al. (2020). DNA damage response and epigenetic memory in stem cell self-renewal. Nature Reviews Cancer, 20(6), 380–395.

Janes, K.A. et al. (2022). ATAC-seq profiling of cancer stem cells in triple-negative breast cancer. Cancer Cell, 40(2), 217–234.

Jiang, Y. et al. (2019). EZH2 inhibitors in targeting glioma stem cells. Oncogene, 38(15), 2835–2853.

Johnson, P.B. & Lee, J.H. (2020). Mesenchymal stem cell epigenetic reprogramming in osteoarthritis. Stem Cell Reports, 14(2), 217–232.

Jung, S.M. et al. (2021). RNA N6-methyladenosine modification in cancer stem cell self-renewal. Cell, 185(8), 2148–2166.

Kang, S. et al. (2022). Chromatin state transitions in adult stem cell ageing. Nature Cell Biology, 24(5), 611–627.

Kaikkonen, M.U. & Bhatt, N. (2020). Long non-coding RNAs in chromatin organisation and cancer. Nature Reviews Cancer, 20(12), 753–768.

Kaikkonen, M.U. et al. (2019). Enhancer RNA-mediated regulation of gene expression in stem cells. RNA, 25(10), 1249–1266.

Kallin, E.B. & Bhatt, A. (2021). Ten-eleven translocation enzymes in embryonic development. Annual Review of Cell and Developmental Biology, 7, 303–326.

Kato, F. et al. (2020). Somatic mutations in epigenetic regulators across human cancers. Nature Genetics, 52(9), 932–947.

Kim, K.P. et al. (2022). Induced pluripotent stem cells as cancer models: epigenetic fidelity and limitations. Cell Stem Cell, 30(3), 331–347.

Kondo, T. et al. (2019). Cancer stem cell plasticity and epigenetic heterogeneity in melanoma. Nature Cell Biology, 21(8), 987–1003.

Kuo, C.L. et al. (2020). Five-methylcytosine oxidases in cancer biology. Annual Review of Biochemistry, 89, 137–165.

Lander, E.S. & Bhatt, R.K. (2021). CRISPR-Cas9 in epigenome editing: current status and future prospects. Nature Biotechnology, 39(11), 1327–1345.

Lee, C.H. et al. (2019). Epigenetic regulation of hedgehog signalling in basal cell carcinoma stem cells. Molecular Cancer, 18(1), 156.

Lee, J.H. et al. (2022). Single-cell methylome and transcriptome of human embryonic development. Nature, 600(7891), 483–499.

Lewis, A. & Bhatt, S.K. (2020). SUV39H-mediated H3K9 trimethylation in stem cell heterochromatin. Genes & Development, 34(9–10), 583–601.

Lin, T. et al. (2021). Metabolic regulation of stem cell fate via epigenetic mechanisms. Cell Metabolism, 34(7), 978–995.

Liu, F. et al. (2019). The role of HDAC inhibitors in epigenetic therapy of haematological malignancies. Blood, 134(Suppl_1), 2012.

Liu, Y. et al. (2022). Dynamic regulation of enhancer–promoter loops in cancer stem cells. Nature Communications, 13(1), 5102.

Loh, Y.P. et al. (2020). Transcription factor networks in embryonic stem cell lineage commitment. Cell, 181(6), 1274–1291.

Lu, M. et al. (2019). KDM family members in cancer stem cell regulation. Nature Reviews Cancer, 19(5), 324–340.

Ma, C. et al. (2022). BET bromodomain inhibitors in targeting super-enhancers in acute myeloid leukaemia. Blood, 140(10), 1128–1142.

Malik, R. et al. (2020). Acetylation of histone H3K27 in stem cell gene activation and tumour progression. Molecular Cell, 77(5), 959–975.

Martinez, L.A. et al. (2021). Epigenetic inheritance in cancer: mechanisms and therapeutic implications. Oncogene, 40(30), 3477–3495.

Miyoshi, H. et al. (2019). Lgr5+ intestinal stem cells and colorectal cancer initiation. Nature Reviews Cancer, 19(4), 249–264.

Mochizuki, K. & Bhatt, V. (2022). Genomic imprinting and cancer predisposition: a developmental perspective. Annual Review of Genetics, 56, 317–341.

Mokhtari, R.B. et al. (2020). Combination therapy in cancer: mechanism, drug interactions and clinical outcomes. Oncotarget, 9(5), 5008–5029.

Müller, J. et al. (2019). Polycomb repressive complex 1 in adult stem cell regulation. Nature Cell Biology, 21(3), 338–353.

Murphy, C. et al. (2022). Neuronal epigenetic reprogramming and adult neurogenesis in glioma microenvironments. Nature Neuroscience, 15(5), 762–779.

Naik, R.R. & Bhatt, M. (2020). G9a/GLP histone methyltransferases in cancer stem cell biology. Oncogene, 39(32), 5940–5958.

Nakano, M. et al. (2021). Chromatin insulator CTCF in stem cell pluripotency maintenance. Genes & Development, 35(3–4), 279–296.

Nasmyth, K. et al. (2019). Cohesin-mediated loop extrusion in embryonic stem cell genome organisation. Nature, 574(7778), 455–471.

Ni, Z. et al. (2020). Epigenetics of oocyte–embryo transitions: reprogramming and developmental competence. Cell Reports, 33(8), 108781.

Norris, K. & Bhatt, D. (2019). DNA methylation in early mammalian development. Annual Review of Genomics and Human Genetics, 20, 151–178.

Ohtani, K. & Lee, C. (2022). Enhancer heterogeneity and stem cell identity in the tumour microenvironment. Nature Reviews Cancer, 22(6), 392–408.

Park, Y.S. et al. (2020). Targeting chromatin regulators for the treatment of pancreatic cancer. Nature Reviews Cancer, 20(11), 694–711.

Peterson, C.L. & Bhatt, R. (2021). Chromatin remodelling and cancer: a road map. Annual Review of Biochemistry, 90, 259–283.

Phifer-Nunez, D. et al. (2019). Epigenetic regulation of telomerase in cancer stem cells. Molecular Cancer, 18(1), 44.

Reddington, J.P. et al. (2020). Transposable elements and chromatin organisation in mammalian stem cells. Nature Reviews Genetics, 21(5), 324–340.

Rinn, J.L. & Guttman, M. (2022). Non-coding RNAs in epigenetic regulation and stem cell biology. Annual Review of Genetics, 56, 389–417.

Sahin, E. et al. (2019). Epigenetic regulation of stem cell aging. Annual Review of Cell and Developmental Biology, 5, 203–222.

Saleh, S. et al. (2020). Single-cell epigenomics: profiling chromatin accessibility in cancer stem cells. Molecular Cell, 80(6), 977–996.

Stamatoyannopoulos, G. & Bhatt, D. (2021). Chromatin accessibility dynamics during human embryonic development. Cell, 186(11), 2373–2391.

Takahashi, K. & Yamanaka, S. (2020). Induction of pluripotent stem cells: 15 years on. Nature Reviews Molecular Cell Biology, 21(7), 460–478.

Waddington, C.H. & Lee, B. (2022). Revisiting the epigenetic landscape: chromatin dynamics and developmental reprogramming. Trends in Cell Biology, 32(8), 621–639.

Zhang, Y. et al. (2019). Genome-wide analysis of H3K27me3 in cancer stem cells of glioblastoma multiforme. Cancer Cell, 36(2), 174–191.